FDA
-
-
-
-
-
-
-
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
-
-
-
-
-
-
-
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
-
-
-
-
-
-
-
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
-
-
-
-
-
-
-
Innate Pharma (IPH) Reports Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101
-
-
-
-
-
-
-
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 202
-
-
-
-
-
-
-
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
-
-
-
-
-
-
-
Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update
-
323,630 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

